JG
RVNC

Jefferies Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

Jefferies Group’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,846
Closed -$30.1K – 2021
2021
Q4 		$30.1K Buy
+1,846
New +$30.8K ﹤0.01% 1540
2015
Q3 		– Sell
-173
Closed -$6K – 3170
2015
Q2 		$6K Buy
+173
New +$4.45K ﹤0.01% 2964
2015
Q1 		– Sell
-100,000
Closed -$1.69M – 2453
2014
Q4 		$1.69M Buy
+100,000
New +$1.75M 0.01% 775

Other funds holding RVNC

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jefferies Group's RVNC Position: Q1 2022 in Review

Jefferies Group sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2022, closing a stake of 1,846 shares — an estimated $30.1K sold.

Jefferies Group first reported a position in RVNC in Q4 2014 and held it in 3 quarters. The position peaked at $1.69M in Q4 2014. 157 funds tracked by Wall St. Rank hold RVNC as of Q1 2022.

  • Jefferies Group reported no remaining Revance Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
  • Jefferies Group sold 1,846 Revance Therapeutics, Inc. shares in Q1 2022, an estimated $30.1K.
  • Jefferies Group first reported a position in Revance Therapeutics, Inc. in Q4 2014 and held it in 3 quarters.
  • Jefferies Group's Revance Therapeutics, Inc. position peaked at $1.69M in Q4 2014.
  • 157 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2022.

Based on Jefferies Group's 13F filing for Q1 2022, filed 16 May 2022.